AUCTORES
Globalize your Research
Journal of Clinical Cardiology and Cardiovascular Interventions
Ernst von Schwarz Schwarz *
Open Access
Review Article

Algorithms to Ageless: AI in Anti-Aging Medicine

Ernst R. von Schwarz [1,2,3]*, Julian Lloyd Bruce [3], Laurent Cleenewerck de Kiev [3]

[1]Cedars Sinai Medical Center, Los Angeles, CA.

[2]Stem Cell & Anti-Aging Institute, Beverly Hills, CA, USA.

[3]Euclid University, Washington DC.

***Corresponding Author:** Ernst von Schwarz Schwarz, Stem Cell & Anti-Aging Institute 324 S. Beverly Drive, #711, Beverly Hills, CA 90212, USA.

Received date: March 13, 2025; **Accepted date:** March 28, 2025; **Published date:** April 15, 2025

Citation: Ernst R. von Schwarz, Julian L. Bruce, Laurent Cleenewerck de Kiev, (2025), Algorithms to Ageless: AI in Anti-Aging Medicine t, *J Clinical Cardiology and Cardiovascular Interventions*, 8(5); **DOI: 10.31579/2641-0419/462**

Abstract

The adoption of artificial intelligence (AI) in medicine in general and in scientific anti-aging efforts in particular represents a new era of research, diagnostics, and therapy. We here review and discuss the AI-driven methodologies that accelerate the identification of therapeutic targets, predictive biomarkers, and precision-driven interventions, as well as recent breakthroughs, including the application of deep learning (DL) algorithms to screen large chemical libraries, leading to the discovery of senolytic compounds that selectively eliminate aging cells. AI-powered biological aging clocks, trained on genomic, proteomic, metabolomic, and epigenomic data, enable accurate predictions of biological age that may help to optimize early intervention strategies for age-related diseases. AI-based bioinformatics platforms have identified novel compounds that enhance collagen synthesis and mitigate oxidative stress, thus offering new avenues for personalized skincare and anti-aging therapeutics.

Issues for clinical application remain, including ethical concerns and a lack of robust validation frameworks, interdisciplinary collaboration, and appropriate education on AI methodologies. Given that aging-related interventions primarily target middle-aged to elderly populations, clinicians must be equipped to respond to patient concerns and communicate AI-generated insights effectively, fostering trust in AI-assisted anti-aging medicine.

Keywords: aging research; anti-aging; artificial intelligence (ai); biological aging clocks; ai-assisted drug discover

Introduction

The utilization of artificial intelligence (AI) has recently entered anti-aging research and therapy. AI-driven methodologies have impacted the discovery of therapeutic interventions targeting the aging process, resulting in advances in drug discovery, biological aging clocks, and a personalized approach to longevity medicine. The American Medical Association (AMA) defines AI's role in healthcare as "augmented intelligence," emphasizing its ability to enhance human decision-making rather than replacing it. Given medicine's innate complexity and unpredictability, the AMA describes AI as a "partnership between man and machine," expanding the boundaries of what healthcare professionals can achieve [1].

AI was successfully used in medicine in the 1970s with MYCIN, an early AI algorithm developed to support and simplify the detection of specific bacterial infections [2]. DXplain, a decision support system developed in 1980, provided differential diagnoses and disease descriptions, gradually expanding its database to over 2,400 conditions [3]. Despite these early applications, limitations in computing power and algorithmic sophistication prevented widespread adoption. However, with advancements in DL and computational modeling in the 2000s, AI's role in medicine evolved, gaining more traction as an indispensable tool in clinical decision-making [4].

AI's impact on anti-aging research is evident in its acceleration of multi-omics data analysis, high-resolution imaging, and predictive modeling [5]. AI-powered aging clocks leverage genomic, epigenomic, proteomic, and metabolomic data to refine biological age predictions, enabling early detection of age-related diseases and developing personalized intervention strategies [6]. Similarly, AI-assisted drug discovery platforms can identify senolytic compounds that focus on cellular senescence, potentially directing targeted anti-aging strategies [7].

AI-driven imaging technologies, such as 3D Line-Field Confocal Optical Coherence Tomography (LC-OCT) and DL-based cellular analysis, augment the dermatologic armamentarium by detecting age-related skin changes at unprecedented resolution, beyond the capacity of the human eye and expertise [8]. Additionally, AI-guided regenerative medicine strategies, including single-cell transcriptomics and machine-learning-driven cellular reprogramming, may offer novel therapeutic tools for longevity interventions [9].

Despite these advancements, numerous challenges remain. AI's clinical adoption is complicated by data standardization issues, algorithmic transparency, and ethical concerns related to patient privacy, bias, and informed consent, among other bioethical concerns. Moreover, the field requires greater interdisciplinary collaboration between AI researchers, biomedical scientists, and clinicians to ensure that AI-driven insights are scientifically rigorous and clinically actionable [5].

Aging

Aging is a natural, continuous process in living organisms that results in declining internal and external functional capacity, persistence, and vitality. Depending on genetic, cellular, and environmental factors, it affects humans at different rates. While aging is a fundamental part of life, research focuses on ways to reverse age-related degeneration of different organ systems, including the skin, blood vessels, heart, and brain tissue [13].

Factors leading to or causing aging include oxidative stress, the accumulation of free radicals, metabolic garbage, shortening of telomeres, vascular stiffness, lack of repair mechanisms, oxygen and energy deprivation, mitochondrial damage, and loss of stem cells in number and quality. These elements ultimately lead to the loss of cellular membrane integrity, cellular damage, and subsequent death.

Increased levels of ROS lead to cellular senescence, a physiological mechanism that prevents cellular proliferation in response to damage incurred during replication. Senescent cells accumulate with age, leading to age-related skin changes and pathologies. The Hayflick limit describes the inability of telomeres to maintain their lengths due to the replication process, causing cells to lose their ability to proliferate and enter a stage of irreversible cell cycle arrest, termed cellular senescence [13].

Senescent cells resist apoptosis and secrete factors that promote inflammation and DNA damage. These cells contribute to tumorigenesis and various age-related malignancies due to the secretion of the senescence-associated secretory phenotype (SASP). Senescent cells are characterized by a persistent DNA damage response, which can also be induced by ionizing radiation, chemotherapeutics, genotoxic stress, and oxidative stress [13]. With the accumulation of senescent cells contributing to age-related diseases, senolytic drugs have proven therapeutic potential in treating these disorders. Senolytic drugs can extend lifespan and delay age-related physical decline in normal mice, suggesting their effectiveness in age-related diseases [14].

AI Utilization in Anti-Aging Research

AI is becoming a useful methodology in anti-aging medicine by integrating non-invasive imaging technologies, synthetic biology, and machine learning (ML) to develop diagnostic tools and therapeutic strategies [15]. AI-assisted techniques currently enhance skin imaging, drug discovery, and cellular-level aging analysis, supporting goal-directed therapies and their efficacy measures [16]. For example, AI imaging techniques can determine collagen content and improvements in circulation to evaluate the effects of anti-aging skin treatments (reference needed).

One of the most promising AI applications in dermatology and aging research is high-resolution skin imaging, used for diagnosis, treatment monitoring, and surgical planning. AI-enhanced Confocal Laser Scanning Microscopy (CLSM) and Multiphoton Laser Scanning Microscopy (MPLSM) allow for detailed visualization of micrometric features within superficial skin layers. Recent advancements, such as 3D Line-Field Confocal Optical Coherence Tomography (LC-OCT), enable ultra-high-resolution imaging of skin histology and cellular structures, significantly improving the ability to assess age-related morphological changes [17].

AI-driven quantitative cellular analysis is increasingly significant in refining aging diagnostics. High-resolution images obtained through LC-OCT and other imaging modalities undergo AI-assisted analysis, enabling measurements of cellular characteristics, including nuclei size, shape, and network atypia. A recent study collected imaging data from three distinct anatomical sites: the upper face at the temple, the central face at the malar region, and the lower jawline at the inferior jaw. The AI analysis identified age-associated changes, such as slight stratum corneum thickening, increased nuclear count, a less dense cellular network, and greater nuclear heterogeneity [18]. These findings demonstrate AI’s capability to quantify and monitor aging at the cellular level, enhancing early detection methods and improving the precision of targeted interventions.

Beyond imaging, AI plays a role in discovering and developing senolytic anti-aging drugs. Combining synthetic biology with ML can identify novel therapeutic agents targeting aging-related processes, such as fibrosis, inflammation, cellular damage, and cancer progression. AI-assisted drug screening platforms can analyze vast chemical libraries and predict compound efficacy and toxicity, significantly accelerating the identification of promising anti-aging therapies [19].

AI Algorithms for Senolytic Drug Development

Senolytic drugs aim to eliminate senescent cells associated with age-related degeneration, such as cardiovascular disorders, neurodegenerative diseases, and possibly cancer [20]. A group at the University of Edinburgh developed a machine learning model to discover new senolytic drugs. The XGBoost AI algorithm recognizes features of chemicals with senolytic activity, using data from more than 2,500 chemical structures for model training. The AI screening identified 21 potential drug candidates for experimental testing. Tests in human cells revealed that three compounds, ginkgetin, periplocin, and oleandrin, could eliminate senescent cells while preserving the integrity of healthy cells. Interestingly, these compounds are naturally derived from traditional herbal medicines, with oleandrin being the most effective [21].

MIT and the Wyss Institute researchers utilized graph neural networks to screen 2,352 compounds for senolytic activity in a model of etoposide-induced senescence. This AI-guided method revealed three highly selective and potent senolytic compounds from a chemical space of over 800,000 molecules. The compounds displayed chemical properties suggestive of high oral bioavailability and favorable toxicity profiles in hemolysis and genotoxicity tests. Structural and biochemical analyses indicated that these compounds bind Bcl-2, a protein that regulates apoptosis and is also a chemotherapy target. Molecular docking simulations and time-resolved fluorescence energy transfer experiments confirmed the binding affinity of these compounds to Bcl-2, highlighting their potential as effective senolytics. Furthermore, in vivo testing in aged mice demonstrated a significant reduction in senescent cell burden and decreased expression of senescence-associated genes in the kidneys [22].

Others confirmed that ouabain, a drug traditionally used to treat heart conditions, has potential senolytic properties due to its ability to induce apoptosis in senescent cells while sparing healthy cells selectively. This effect is mediated by inhibiting the Na, K-ATPase pump, which activates signaling pathways involving Src, p38, Akt, and Erk2. These pathways are crucial for the survival of senescent cells, and their inhibition by ouabain triggers cell death. Ouabain's senolytic activity is enhanced by ATP1A1 knockdown and can be mitigated by supplemental potassium. This discovery highlights the potential of repurposing existing drugs for senolytic applications, offering a promising avenue for developing new anti-aging therapies [23].

AI to Promote Healthy Skin

AI has emerged as a tool increasingly used in dermatology and oncology, significantly enhancing skin health assessment, cancer detection, and precision treatment strategies [24]. AI’s ability to analyze high-resolution dermatological images, integrate multi-omic datasets, and predict treatment responses has established it as a cornerstone in modern dermatologic and oncologic research [25].

DL models, particularly convolutional neural networks (CNNs), have enabled accurate classification of skin lesions. A landmark study by Esteva et al. (2021) employed a deep CNN trained on over 129,000 clinical images to distinguish between benign and malignant skin conditions. The AI model achieved a diagnostic accuracy comparable to board-certified dermatologists, outperforming general practitioners in melanoma detection with an AUC (area under the curve) of 91.6% [26].

Tschandl et al. (2023) examined the efficacy of AI in detecting skin cancers (NMSC) and melanoma using dermoscopic images from 15,000 patients. The authors found that AI-assisted diagnostic workflows improved clinician performance by reducing false negatives and increasing early detection rates. The AI model demonstrated a diagnostic sensitivity of 92.4% and specificity of 89.1%, outperforming independent human dermatologists in large-scale validation trials [27].

Moreover, spectral AI imaging technologies have been integrated into non-invasive diagnostic tools such as reflectance confocal microscopy (RCM) and multiphoton tomography (MPT). These techniques use AI-enhanced feature recognition to detect pre-malignant and malignant lesions with superior accuracy. Studies have demonstrated that AI-powered RCM can distinguish basal cell carcinoma from benign skin conditions with 95% accuracy, significantly improving the early detection of cutaneous malignancies [28].

Accelerated Aging

Cancer and treatments such as chemotherapy, radiation therapy, and immunotherapy have been shown to accelerate biological aging processes [29]. This phenomenon, known as accelerated aging, is characterized by the early onset of age-related conditions such as frailty, sarcopenia, cardiac dysfunction, and cognitive impairment [30]. The mechanisms underlying accelerated aging include increased cellular senescence, DNA damage, oxidative stress, and chronic inflammation [29]. For instance, chemotherapy and radiation therapy can induce DNA damage and oxidative stress, leading to the accumulation of senescent cells. These senescent cells secrete pro-inflammatory cytokines and other factors, contributing to tissue dysfunction and the development of age-related diseases [30].

The accelerated aging observed in cancer survivors underscores the importance of further anti-aging research and interventions utilizing AI. AI applications in anti-aging research have shown promise in identifying biomarkers of aging, developing geroprotectors, and generating dual-purpose therapeutics targeting aging and disease [5]. For example, deep learning models have been used to develop deep aging clocks, which predict biological age based on various biomarkers. These models can help identify individuals at risk of accelerated aging and guide personalized interventions to mitigate age-related decline [31].

AI for Treatment Optimization

AI has paved the way for updated oncologic treatment strategies and protocols by integrating genomic, proteomic, and histopathological data to personalize cancer therapies. In 2022, Liu et al. utilized a deep learning-based multi-omics analysis to identify melanoma subtypes that respond to immunotherapy. This approach predicted patient responses to checkpoint inhibitors. The model, trained on 20,000 genomic datasets, accurately stratified melanoma patients into high- and low-responders with an accuracy of 87.9%. This stratification led to improved treatment selection and increased patient survival rates [32].

ML-assisted drug discovery has also accelerated the identification of novel targeted therapies for aggressive skin cancers. AI-based molecular docking simulations have led to the discovery of new-generation BRAF and MEK inhibitors with enhanced specificity and reduced off-target toxicity. In 2023, Patel et al. demonstrated that AI-driven computational chemistry platforms could reduce the drug discovery timeline by 70%, expediting the development of next-generation melanoma treatments [33].

AI-powered predictive analytics have also been integrated into radiotherapy planning for cutaneous malignancies, optimizing dose distribution and minimizing healthy tissue damage. A randomized clinical trial conducted at MD Anderson Cancer Center in 2023 found that AI-assisted radiotherapy planning reduced radiation toxicity by 30%, significantly improving patient tolerability and treatment outcomes [34].

AI in Personalized Anti-Aging Interventions

AI technology has the potential to develop personalized skincare regimens and recommend anti-aging treatments by analyzing genetic predispositions, environmental factors, and individual skin profiles. AI-driven platforms such as SkinGenie and L'Oréal's Modiface use deep neural networks trained on dermatological imaging datasets to predict wrinkle formation, hyperpigmentation patterns, and elasticity loss based on individual skin biomarkers. These models have enabled customized recommendations for topical treatments, non-invasive procedures, and lifestyle modifications to slow skin aging [35].

Similarly, machine learning algorithms analyze proteomic and transcriptomic data to identify novel anti-aging compounds. Wang et al. used an AI-assisted screening platform to discover plant-derived bioactive molecules that modulate collagen synthesis and reduce oxidative stress in dermal fibroblasts. This resulted in enhanced skin firmness and reduced fine lines [36].

Furthermore, AI-powered microfluidic sensors are being integrated into smart skincare devices that provide real-time biometric feedback on skin hydration, UV exposure, and oxidative damage levels. These devices leverage predictive modeling to recommend personalized antioxidant regimens and skin rejuvenation therapies, marking a paradigm shift toward precision dermatology [37].

Deep Learning Frameworks in Biological Age Prediction

A notable development in this domain is the introduction of DeepAge, a DL framework that employs Temporal Convolutional Networks (TCNs) to predict biological age from DNA methylation profiles. Traditional epigenetic clocks often rely on linear regression models, which may not fully capture methylation data's complex, non-linear interactions. DeepAge addresses this limitation by utilizing dilated convolutions to effectively capture long-range dependencies between CpG sites, thereby enhancing the accuracy of biological age estimation. This approach has demonstrated superior performance to existing models, providing a more nuanced understanding of aging [38].

Complementing Deep Age, the Deep MAge model integrates DL techniques to develop a methylation aging clock. This model has shown biological relevance by assigning higher predicted ages to individuals with various health-related conditions, such as ovarian cancer, irritable bowel diseases, and multiple sclerosis. The ability of Deep MAge to correlate elevated biological age with these conditions underscores its potential utility in early disease detection and monitoring [39].

AI-Driven Biomarker Discovery, Validation, and Aging Clocks

Utilizing advanced AI techniques for biomarker discovery has revolutionized the analysis of complex biological data, particularly in aging research. By leveraging ML and DL techniques, researchers can efficiently process multi-omics datasets, including genomics, transcriptomics, proteomics, and metabolomics, to uncover potential anti-aging biomarkers more precisely. AI-driven multi-omics integration allows for a holistic understanding of aging mechanisms, facilitating the identification of novel therapeutic targets and personalized interventions [31].

DL models, particularly those employing neural networks with multiple layers, have played a crucial role in developing aging clocks that predict biological age based on molecular biomarkers. DeepQA, a recently developed AI framework, utilizes transcriptomic data to estimate biological age. By incorporating a Hinge-Mean-Absolute-Error loss function, DeepQA can train on both healthy and unhealthy subjects across multiple cohorts, significantly reducing bias in biological age estimation. Empirical evaluations have demonstrated that DeepQA outperforms conventional aging clocks, providing a more accurate assessment of biological age [40].

Beyond aging clocks, explainable AI (XAI) techniques have identified biologically and clinically actionable biomarkers, supporting their translational potential in precision medicine [41].

AI has also advanced the integration of multi-omics data for biomarker discovery, an essential step in understanding the complexity of aging. By combining diverse biological layers, ML models can manage high-dimensional and heterogeneous datasets, uncovering intricate molecular interactions contributing to aging and age-related diseases. A notable example is Deep KEGG, a DL framework for interpretable multi-omics integration. This model enhances the prediction of disease outcomes and facilitates the discovery of therapeutic targets by mapping biomolecular interactions within large datasets [42].

AI-based multi-omics fusion models can predict biological age and disease susceptibility more accurately than single-omics approaches. These integrative models improve biomarker reliability by cross-validating signals across multiple biological layers, ensuring robust and reproducible biomarker identification [43].

AI in Biomarker Validation

Validation of identified biomarkers is critical to ensure their reliability and clinical relevance. AI enhances this process by constructing data-driven frameworks that utilize independent datasets and cross-validation techniques, improving the robustness of biomarker validation and facilitating their translation into clinical practice [44]. One application of AI in this area involves the validation of biomarkers linked to cellular senescence. Machine learning algorithms have been utilized to analyze large-scale single-cell RNA sequencing data, allowing for precise identification of senescence-associated gene expression patterns. An example is the development of SenPred, a machine learning pipeline designed to detect senescent fibroblasts based on single-cell transcriptomic data. SenPred achieves high accuracy by analyzing 2D and 3D cultured fibroblasts, significantly improving the detection of senescent cells in vivo. This approach highlights the potential of AI to enhance our understanding of cellular aging and develop targeted anti-aging therapies [45].

AI-driven models have also been utilized to validate biomarkers of brain aging. In a study involving 2,314 individuals, AI was used to analyze neuroimaging data, revealing associations between brain biological age and the presence of Alzheimer's disease biomarkers, such as beta-amyloid and tau proteins. The AI model could non-invasively track the pace of brain changes using MRI scans, providing a powerful tool for understanding, preventing, and treating cognitive decline. Additionally, the study found that faster brain aging closely correlates with a higher risk of cognitive impairment, highlighting the potential of AI in early diagnosis and intervention for neurodegenerative diseases [46].

Moreover, AI has facilitated the validation of transcriptomic signatures indicative of cellular senescence. Senescence-related genes, such as Glipr1, Clec12a, and Phlda3, were identified by integrating single-cell and bulk RNA sequencing data in mouse liver tissues. These genes are consistently expressed in senescent cells across different experimental conditions, including stress-induced premature senescence. Fluorescence in situ hybridization (FISH) confirmed the presence of cells with abundant Glipr1, Clec12a, and Phlda3 mRNA in aged mouse liver tissues, further validating their role as markers of cellular senescence [47].

Discussion

Applications of AI in Anti-Aging Medicine

Advances in generative modeling, multimodal AI integration, and dynamic biological aging clocks will shape the future of AI in anti-aging research. Generative Adversarial Networks (GANs) and Large Language Models (LLMs) trained on vast biomedical datasets will continue to drive novel protein-ligand interaction predictions, drug repurposing strategies, and synthetic biological modeling. Recent studies have shown that GANs can generate synthetic transcriptomic and proteomic profiles, allowing researchers to explore hypothetical aging interventions without requiring large-scale human trials [31]. Multi-omics-driven AI models will provide deeper insights into the interplay between genetics, epigenetics, metabolism, and protein function in aging. AI-powered integrative aging clocks, capable of analyzing genomic, proteomic, metabolomic, and transcriptomic data, will improve the accuracy of biological age estimation and risk stratification for age-related diseases. Combining longitudinal health data with AI-driven predictions will enable real-time monitoring of biological aging, allowing for highly individualized longevity strategies [5].

Beyond discovery and modeling, AI is expected to enhance regenerative medicine and cellular reprogramming technologies. Recent breakthroughs in AI-driven single-cell transcriptomics have allowed for identifying cell fate transitions during aging, providing the foundation for rejuvenation therapies and stem cell-based interventions. These AI-driven insights could pave the way for therapies that reverse cellular senescence, improve tissue regeneration, and extend health span [48].

Challenges and Limitations of AI in Anti-Aging Medicine

Despite advances in AI-driven anti-aging research, several scientific and technical challenges persist. Data quality and standardization are among the most pressing issues, threatening the accuracy and proper outputs of even the most robust models. Aging research generates vast, heterogeneous datasets that vary in quality, format, and completeness. AI models require large, high-quality, well-annotated datasets to make reliable predictions. However, inconsistencies in multi-omics data collection, imaging modalities, and clinical parameters can introduce biases or lead to misleading conclusions. Ensuring standardized data pipelines and developing federated learning approaches that enable secure data sharing without compromising privacy are critical to improving AI model reliability [5].

Another challenge is the lack of AI explainability and interpretability. Many deep learning models operate as "black boxes," producing highly accurate predictions without providing insight into the underlying biological mechanisms of aging. This opacity limits their clinical adoption, as physicians and researchers may hesitate to trust models they cannot fully understand. Developing XAI frameworks, which offer transparency into how AI models generate predictions, is essential for increasing clinician confidence and facilitating regulatory approval of AI-driven aging interventions [42].

Ethical, regulatory, and privacy concerns also pose significant risks. AI applications in anti-aging medicine involve analyzing sensitive personal health data and raising issues related to data security, informed consent, and algorithmic bias. Regulatory frameworks for AI-driven longevity interventions are still evolving, and transparency in AI decision-making is crucial for public trust. Ethical guidelines must ensure that AI-driven longevity medicine balances innovation with patient safety, equitable access to interventions, and fair treatment across diverse populations [49]

Education on AI Technologies

AI models must be co-developed with physicians, biomedical researchers, and ethicists to ensure clinical relevance and real-world applicability. Interdisciplinary collaboration between AI engineers and healthcare professionals can facilitate the creation of user-friendly and transparent AI systems, essential for widespread adoption in aging medicine. AI-generated recommendations must be interpretable and contextualized within established medical knowledge so physicians can effectively communicate insights to their patients and make informed clinical decisions. Given that patients most interested in anti-aging therapies are often middle-aged to elderly and are well-knowledgeable about their health condition, healthcare professionals must be able to explain what AI can provide and how [50]. Currently, this might be challenging since clinicians lack any formal appropriate training in AI methodologies, requiring hands-on training in AI technology and methods, model validation techniques, and the critical evaluation of AI-generated predictions [51].

As AI becomes increasingly utilized in conjunction with personalized anti-aging interventions, clinicians must be equipped with effective communication strategies to explain AI-driven longevity assessments in clear and accessible terms. This includes interpreting predictive models, discussing uncertainties, and setting realistic expectations for AI-enhanced interventions. Training programs should prepare healthcare providers to navigate AI-generated longevity strategies' ethical and clinical implications, ensuring patients receive accurate, balanced, and actionable information [52, 53].

Strategies and Recommendations for Advancing AI Integration

We need a multi-faceted approach involving technology, collaboration, and regulation to tackle the challenges in AI-driven anti-aging medicine. Institutions should use standardized methods for collecting and integrating multi-omics data to improve quality and consistency. Federated learning and decentralized data systems can support collaborative research while protecting patient privacy and adhering to data laws [5]. Developing XAI tools is crucial for transparency, helping clinicians understand and trust AI predictions. Open-source frameworks and clear documentation will enhance reproducibility and peer review, ensuring clinical usefulness across different populations [41, 42].

Long-term solutions require changes in education and regulation. Adding AI training to medical education and ongoing training programs can bridge the gap between clinicians and data scientists. Interdisciplinary teams, including ethicists, computer scientists, and healthcare professionals, should co-develop AI tools to ensure they are clinically relevant and ethically sound [51-53]. Global regulatory bodies need to create unified standards for approving, auditing, and monitoring AI-based anti-aging treatments to ensure safety, fairness, and accountability. These coordinated efforts are essential for AI to promote health and longevity effectively [49].

Conclusion

AI is revolutionizing anti-aging research and therapy, offering unprecedented insights into aging mechanisms, therapeutic discovery, and precision-driven and personalized longevity interventions. The application of AI-driven advancements such as senolytic compound discovery, biological aging clocks, and personalized longevity medicine augments early disease detection and extending healthspan. Data standardization, AI model explainability, and ethical concerns regarding privacy and bias must be addressed for broader clinical adoption. Clinician education and interdisciplinary collaboration are crucial to integrate AI into anti-aging medicine.

Key Points:

1. AI-driven methodologies are accelerating the identification of therapeutic targets, predictive biomarkers, and precision-driven interventions in anti-aging research.
2. Deep learning algorithms have been applied to screen large chemical libraries, leading to the discovery of senolytic compounds that selectively eliminate aging cells.
3. AI-powered biological aging clocks use multi-omics data to predict biological age accurately, aiding in early intervention strategies for age-related diseases.
4. AI-assisted drug discovery platforms have identified novel compounds that enhance collagen synthesis and mitigate oxidative stress, offering new avenues for personalized skincare and anti-aging therapeutics.
5. Challenges for clinical application of AI in anti-aging medicine include ethical concerns, data standardization issues, and the need for interdisciplinary collaboration and education on AI methodologies.

Issues Relating to Journal Policies: We have carefully reviewed the **Clinical Cardiology and Cardiovascular Interventions** policies and guidelines and have ensured that this manuscript complies with all submission requirements. There are no issues relating to journal policies that need to be addressed

Declaration of Potential Competing Interests: No conflicts of interest exist by any of the authors.

Author Approval and Confirmation of Originality: We confirm that all authors approve the submission of this manuscript to the **Clinical Cardiology and Cardiovascular Interventions**. Additionally, we affirm that the content of this manuscript has not been published or submitted for publication elsewhere.

Declarations:

- Ethics approval and consent to participate: No human or animal subjects were used in this literature review; therefore, ethical approval and participation consent are unnecessary.
- Consent for publication: No personal details, images, or videos of any individual were included in this manuscript.
- Availability of data and material: Not applicable.
- Competing interests: No conflicts of interest.
- Funding: No external funding was received to conduct this research.
- Authors' contributions: Ernst R. von Schwarz, MD, PhD is the primary author, along with Julian Bruce who together conducted the initial research and drafted of the manuscript. Laurent Cleenewerck de Kiev, PhD, FRSPH performed significant editing and additional research to tie the manuscript together before final review and approval by all three authors.
- Acknowledgements: There are no acknowledgements.
- Studies involving plants: Not applicable, as this study does not involve plants.

References

1. Smith, T. M. (2023). Healthcare AI is here. So is new guidance to use it effectively. American Medical Association.
2. Shortliffe, E. H. (2019). The enduring legacy of MYCIN: AI in medical diagnosis. Journal of Artificial Intelligence Research, 65, 123-145.

3. Barnett, G. O., Cimino, J. J., Hupp, J. A., & Hoffer, E. P. (2016). DXplain: An evolving diagnostic decision-support system. Journal of the American Medical Informatics Association, 23(4), 738-746.
4. Keragon, J. (2024). The history of AI in healthcare: Overcoming early limitations. Journal of Healthcare Technology, 12(3), 45-67.
5. National University of Singapore, Yong Loo Lin School of Medicine. (2025). Transforming Longevity Research: AI Paves the Way for Personalized Anti-Aging Treatments.
6. King's College London. (2024). AI-based aging clocks offer insights into health and lifespan.
7. Labiotech.eu. (2024). Five AI drug discovery companies you should know about.
8. Frontiers. (2023). Towards AI-driven longevity research: An overview.
9. AI Competence Center. (2025). Age Reversal With AI: Cellular Reprogramming Explained.
10. Hajam, Y. A., Rani, R., Ganie, S. Y., Sheikh, T. A., Javaid, D., Qadri, S. S., ... & Reshi, M. S. (2022). Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives. Cells, 11(2), 552.
11. Ziada, A. S., Smith, M. R., & Côté, H. C. F. (2020). Updating the Free Radical Theory of Aging. Frontiers in Cell and Developmental Biology, 8, 575645.
12. Palma, F. R., Gantner, B. N., Sakiyama, M. J., Kayzuka, C., Shukla, S., Lacchini, R., ... & Bonini, M. G. (2024). ROS production by mitochondria: function or dysfunction? Oncogene, 43, 295-303.
13. National Institute on Aging. (2021). Does cellular senescence hold secrets for healthier aging?
14. Preventive Medicine Daily. (2024). Top Senolytic Drugs – Promising Developments in Aging Research.
15. TRENDS Research & Advisory. (2024). AI and Longevity: Can Artificial Intelligence Help Humans Live Longer?
16. Mayo Clinic Press. (2024). AI in healthcare: The future of patient care and health management.
17. EMJ. (2024). AI-Driven Advances in Dermatological Imaging.
18. ScienceDaily. (2025). Automatic cell analysis with the help of artificial intelligence.
19. Longevity.Technology. (2023). AI identifies three new anti-aging senolytic candidates.
20. Scharping, N. (2020). Senolytics: A New Weapon in the War on Aging. Discover Magazine.
21. IBM. (2025). What is XGBoost?
22. Wong, F., Omori, S., Donghia, N. M., Zheng, E. J., & Collins, J. J. (2023). Artificial intelligence identifies new small-molecule senolytics. Nature Aging.
23. Guerrero, A., Herranz, N., Sun, B., Wagner, V., Gallage, S., Guiho, R., ... & Gil, J. (2024). Cardiac glycosides are broad-spectrum senolytics. Nature Metabolism.
24. Stanford Medicine News Center. (2024). AI improves accuracy of skin cancer diagnoses in Stanford Medicine-led study.
25. MC Methods. (2024). Artificial intelligence for omics data analysis.
26. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2021). Dermatologist-level classification of skin cancer with deep neural networks. Nature Medicine, 23(8), 865-870.
27. Tschandl, P., Rinner, C., Apalla, Z., Argenziano, G., Codella, N., Halpern, A., ... & Kittler, H. (2023). Human–computer collaboration for skin cancer recognition. The Lancet Digital Health, 5(1), e42-e51.
28. Rajpara, S. M., Botting, J. R., & Marsden, J. R. (2022). Reflectance confocal microscopy for the diagnosis of basal cell carcinoma: a systematic review and meta-analysis. Journal of Investigative Dermatology, 142(1), 23-30.
29. Bhatia, R., Holtan, S., El Jurdi, N., Prizment, A., & Blaes, A. (2022). Do Cancer and Cancer Treatments Accelerate Aging? Current Oncology Reports, 24, 1401-1412.
30. UCLA Health News. (2024). Addressing the challenge of accelerated aging in breast cancer survivors. Retrieved from https://www.uclahealth.org/news/article/addressing-challenge-accelerated-aging-breast-cancer.
31. Wilczok, D. (2025). Deep learning and generative artificial intelligence in aging research and healthy longevity medicine. Aging Review, 17(1), 251-275.
32. Liu, Y., et al. (2022). Deep learning-based multi-omics analysis identifies immunotherapy-responsive melanoma subtypes. Nature Cancer.
33. Patel, R., Sharma, K., Lee, H., & Kim, D. (2023). AI-driven computational chemistry for accelerating targeted therapy discovery in melanoma. Journal of Molecular Medicine, 101(4), 567–582.
34. Kawamura, M., Kamomae, T., Yanagawa, M., Kamagata, K., Fujita, S., Ueda, D., Matsui, Y., Fushimi, Y., Fujioka, T., & Nozaki, T. (2024). Revolutionizing radiation therapy: the role of AI in clinical practice. Journal of Radiation Research, 65(1), 1-9.
35. L'Oréal Research. (2023). AI-driven platforms for personalized skincare and anti-aging treatments. Journal of Cosmetic Dermatology.
36. Wang, Y., Li, X., & Zhang, H. (2023). AI-assisted screening of plant-derived bioactive molecules for anti-aging. Experimental Dermatology.
37. Kim, J., Park, S., & Lee, H. (2023). AI-powered microfluidic sensors in smart skincare devices. Nature Biomedical Engineering.
38. Dip, S. A., Ma, D., & Zhang, L. (2024). DeepAge: Harnessing Deep Neural Network for Epigenetic Age Estimation From DNA Methylation Data of Human Blood Samples. Proceedings of the AAAI Symposium Series, 4(1), 267-274.
39. Galkin, F., Mamoshina, P., Kochetov, K., Sidorenko, D., & Zhavoronkov, A. (2021). DeepMAge: A Methylation Aging Clock Developed with Deep Learning. Aging and Disease, 12(5), 1252-1262.
40. Qi, H., Zhao, H., Li, E., Lu, X., Yu, N., Liu, J., & Han, J. (2025). DeepQA: A unified transcriptome-based aging clock using deep neural networks. Aging Cell.
41. Temkov, S. (2024). Explainable AI for discovering disease biomarkers: A survey. EAI/Springer Innovations in Communication and Computing, 185-192.
42. Agarwal, N., Nupur, P. K., & Mishra, S. K. (2024). Artificial intelligence and machine learning for analysis of multi-omics. In Multi-Omics Analysis of the Human Microbiome (pp. 339-354).
43. Leng, D., Zheng, L., Wen, Y., Zhang, Y., Wu, L., Wang, J., Zhang, Z., He, S., & Bo, X. (2022). A benchmark study of deep learning-based multi-omics data fusion methods for cancer. Genome Biology, 23, 171.
44. Llorente-Saguer, I., & Oxtoby, N. P. (2024). A data-driven framework for biomarker discovery applied to optimizing modern clinical and preclinical trials on Alzheimer's disease. Brain Communications, 6(6), fcae438.
45. Mahmud, S., Zheng, C., Santiago, F. E., Zhang, L., Robbins, P. D., & Dong, X. (2024). A machine learning approach identifies cellular senescence on transcriptome data of human cells in vitro. GeroScience.
46. Irimia, A., & Newcomb, B. (2025). New AI model measures how fast the brain ages. Proceedings of the National Academy of Sciences.

47. Olascoaga, S., Konigsberg, M., Espinal-Enríquez, J., Tovar, H., Matadamas-Martínez, F., Pérez-Villanueva, J., & López-Díaz Guerrero, N. E. (2025). Transcriptomic signatures and network-based methods uncover new senescent cell anti-apoptotic pathways and senolytics. FEBS Journal.
48. RoX818. (2025). Age reversal with AI: Cellular reprogramming explained. AI Competence.
49. McNellis, C. (2024). Reframing aging: Through the lens of ethical artificial intelligence. Innovation in Aging, 8(Supplement_1), 1215.
50. Harvard Medical School. (2025). AI in Clinical Medicine.
51. American Medical Association. (2024). Artificial Intelligence in HealthCare Series.
52. Transforming Longevity Research: AI Paves the Way for Personalized Anti-Aging Treatments. National University of Singapore, Yong Loo Lin School of Medicine. January 29, 2025
53. A digital (r)evolution: introducing The Lancet Digital Health. The Lancet Digital Health. 2024.

DOI:10.31579/2641-0419/462